Aurobindo shares in decline as details of FDA warning emerge
This article was originally published in Scrip
Executive Summary
Shares of Aurobindo Pharma slid sharply on Indian bourses after the company said that a US FDA warning letter had also sought a "detailed action plan" for improvement for packaging and labelling compliance at one of its facilities.